Citations

Clear

9383 citation(s) found for "Thomas, PS".

Long-Term Update of US GI Intergroup RTOG 98-11 Phase III Trial for Anal Carcinoma: Survival, Relapse, and Colostomy Failure With Concurrent Chemoradiation Involving Fluorouracil/Mitomycin Versus Fluorouracil/Cisplatin
Gunderson, Leonard L., Winter, Kathryn, Pedersen, John E., Moughan, Jennifer, Benson, Al B. , Thomas, Charles R., Haddock, Michael G. , Rich, Tyvin A. , Willett, Christopher G. , Ajani, Jaffer A. , Mayer, Robert J.

Mayo Clinic

Journal of Clinical Oncology | November 14, 2012 | Volume: 30 | Issue: 35 | Pages: 4344-4351

10.1200/jco.2012.43.8085 | PMID 23150707 Get It

PurposeOn initial publication of GI Intergroup Radiation Therapy Oncology Group (RTOG) 98-11 [A Phase III Randomized Study of 5-Fluorouracil (5-FU), Mitomycin, and Radiotherapy Versus 5-Fluorouracil, Cisplatin and Radiotherapy in Carcinoma of the Anal Canal], concurrent chemoradiation (CCR) with fluorouracil (FU) plus mitomycin (MMC) decreased colostomy failure (CF) when compared with induction plus concurrent FU plus cisplatin (CDDP), but did not significantly impact disease-free survival (DFS) or overall survival (OS) for anal canal carcinoma. The intent of the updated analysis was to determine the long-term impact of treatment on survival (DFS, OS, colostomy-free survival [CFS]), CF, and relapse (locoregional failure [LRF], distant metastasis) in this patient group.Patients and MethodsStratification factors included sex, clinical node status, and primary size. DFS and OS were estimated univariately by the Kaplan-Meier method, and treatment arms were compared by log-rank test. Time to relapse and CF were estimated by the cumulative incidence method and treatment arms were compared by using Gray's test. Multivariate analyses used Cox proportional hazard models to test for treatment differences after adjusting for stratification factors.ResultsOf 682 patients accrued, 649 were analyzable for outcomes. DFS and OS were statistically better for RT + FU/MMC versus RT + FU/CDDP (5-year DFS, 67.8% v 57.8%; P = .006; 5-year OS, 78.3% v 70.7%; P = .026). There was a trend toward statistical significance for CFS (P = .05), LRF (P = .087), and CF (P = .074). Multivariate analysis was statistically significant for treatment and clinical node status for both DFS and OS, for tumor diameter for DFS, and for sex for OS.ConclusionCCR with FU/MMC has a statistically significant, clinically meaningful impact on DFS and OS versus induction plus concurrent FU/CDDP, and it has borderline significance for CFS, CF, and LRF. Therefore, RT + FU/MMC remains the preferred standard of care.
Fat mass and obesity gene and cognitive decline
Bressler, Jan , Fornage, Myriam , Demerath, Ellen W. , Monda, Keri L., Penman, Alan D. , Boerwinkle, Eric , Knopman, David S. , North, Kari E. , Mosley, Thomas H.

Mayo Clinic

Neurology | November 8, 2012 | Volume: 80 | Issue: 1 | Pages: 92-99

10.1212/wnl.0b013e3182768910 | PMID 23136261 Get It

A multi-centre clinico-genetic analysis of the VPS35 gene in Parkinson disease indicates reduced penetrance for disease-associated variants
Sharma, Manu , Aasly, Jan , Annesi, Grazia , Brice, Alexis , Bozi, Maria , Barcikowska, Maria , Crosiers, David , Clarke, Carl E , Facheris, Maurizio , Farrer, Matthew J. , Garraux, Gaëtan , Gispert, Suzana, Auburger, Georg , Vilariño‐Güell, Carles , Hicks, Andrew A. , Hattori, Nobutaka , Jeon, Beom S., Jamrozik, Zygmunt , Krygowska‐Wajs, Anna, Lesage, Suzanne , Lill, Christina M. , Lin, Juei‐Jueng , Lynch, Timothy , Lichtner, Peter , Lang, Anthony E. , Libioulle, Cécile , Murata, Miho, Mok, Vincent , Jasińska‐Myga, Barbara, Mellick, George D. , Morrison, Karen , Meitnger, Thomas, Zimprich, Alexander , Opala, Grzegorz, Pramstaller, Peter P. , Pichler, Irene , Park, Sung Sup , Quattrone, Aldo , Ross, Owen A. , Stockton, Joanne , Satake, Wataru , Silburn, Peter A., Strom, Tim M., Theuns, Jessie , Tan, Eng King, Tomiyama, Hiroyuki , Uitti, Ryan J. , Broeckhoven, Christine Van , Wirdefeldt, Karin , Xiromerisiou, Georgia , Yomono, Harumi, Yueh, Kuo-Chu, Zhao, Yi , Gasser, Thomas , Maraganore, Demetrius M. , Krüger, Rejko , Ioannidis, John P. A. , Bertram, Lars , Hadjigeorgiou, Georgios M. , Rogaeva, Ekaterina A. , Stefanis, Leonidas , Toda, Tatsushi , Wszołek, Zbigniew K. , Lang, Anthony E , Ross, Owen A , Zimprich, Alexander , Brice, Alexis

Mayo Clinic

Journal of Medical Genetics | November 2, 2012 | Volume: 49 | Issue: 11 | Pages: 721-726

10.1136/jmedgenet-2012-101155 | PMID 23125461 Get It

Background Two recent studies identified a mutation (p.Asp620Asn) in the vacuolar protein sorting 35 gene as a cause for an autosomal dominant form of Parkinson disease . Although additional missense variants were described, their pathogenic role yet remains inconclusive. Methods and results We performed the largest multi-center study to ascertain the frequency and pathogenicity of the reported vacuolar protein sorting 35 gene variants in more than 15,000 individuals worldwide. p.Asp620Asn was detected in 5 familial and 2 sporadic PD cases and not in healthy controls, p.Leu774Met in 6 cases and 1 control, p.Gly51Ser in 3 cases and 2 controls. Overall analyses did not reveal any significant increased risk for p.Leu774Met and p.Gly51Ser in our cohort. Conclusions Our study apart from identifying the p.Asp620Asn variant in familial cases also identified it in idiopathic Parkinson disease cases, and thus provides genetic evidence for a role of p.Asp620Asn in Parkinson disease in different populations worldwide.
Migraine headache is present in the aura phase
Hansen, Jakob Møller , Silberstein, Stephen D., Saper, Joel R., Aurora, Sheena K. , Goadsby, Peter J. , Charles, Andrew , Lipton, Richard B. , Dodick, David W. , Goadsby, Peter J , Charles, Andrew

Mayo Clinic

Neurology | November 1, 2012 | Volume: 79 | Issue: 20 | Pages: 2044-2049

10.1212/wnl.0b013e3182749eed | PMID 23115208 Get It

Cobalt and Chromium Measurement in Patients with Metal Hip Prostheses
Estey, Mathew P., Straeten, Catherine Van Der , Tower, Stephen S. , Hart, Alister , Moyer, Thomas P. , Diamandis, Eleftherios P.

Mayo Clinic

Clinical Chemistry | November 1, 2012 | Volume: 59 | Issue: 6 | Pages: 880-886

10.1373/clinchem.2012.193037 | PMID 23115056 Get It

Ticlopidine-, Clopidogrel-, and Prasugrel-Associated Thrombotic Thrombocytopenic Purpura: A 20-Year Review from the Southern Network on Adverse Reactions (SONAR)
Jacob, Sony, Dunn, Brianne L., Qureshi, Zaina P. , Bandarenko, Nicholas, Kwaan, Hau C. , Pandey, Dilip K. , McKoy, June M. , Barnato, Sara E., Winters, Jeffrey L. , Cursio, John , Weiss, Ivy, Raife, Thomas J. , Carey, Patricia M. , Kiss, Joseph E. , Danielson, Constance, Clark, William F. , Rock, Gail, Fujimura, Yoshihiro , Zheng, X. Long , Chen, Hao , Chen, Fei , Armstrong, John, Raisch, Dennis W., Bennett, Charles L. , Sarode, Ravi , Ortel, Thomas L. , Rock, Gail, Matsumoto, Masanori , Winters, Jeffrey L , Zheng, X Long

Mayo Clinic

Seminars in Thrombosis and Hemostasis | October 30, 2012 | Volume: 38 | Issue: 08 | Pages: 845-853

10.1055/s-0032-1328894 | PMID 23111862 Get It

Percutaneous Renal Cryoablation After Partial Nephrectomy: Technical Feasibility, Complications and Outcomes
Hegg, Ryan, Schmit, Grant D. , Boorjian, Stephen A. , McDonald, Robert J. , Weisbrod, Adam J. , Callstrom, Matthew R. , Atwell, Thomas D. , Thompson, R. Houston, Kurup, A. Nicholas

Mayo Clinic

Journal of Urology | October 30, 2012 | Volume: 189 | Issue: 4 | Pages: 1243-1248

10.1016/j.juro.2012.10.066 | PMID 23123377 Get It

Integrative Epigenomic Analysis Identifies Biomarkers and Therapeutic Targets in Adult B-Acute Lymphoblastic Leukemia
Geng, Huimin , Brennan, Sarah, Milne, Thomas A. , Chen, Wei‐Yi , Li, Yushan , Hurtz, Christian , Kweon, Soo-Mi, Zickl, Lynette, Shojaee, Seyedmehdi, Biswas, Debabrata, Yuan, Xin , Racevskis, Janis, Ketterling, Rhett P. , Luger, Selina M. , Tallman, Martin S. , Rowe, Jacob M. , Litzow, Mark R. , Allis, C. David, Müschen, Markus , Paietta, Elisabeth , Elemento, Olivier , Melnick, Ari , Neuberg, Donna , Huang, Chuanxin , Lazarus, Hillard M. , Guzmán, Mónica L. , Roeder, Robert G. , Melnick, Ari , Ketterling, Rhett P

Mayo Clinic

Cancer Discovery | October 30, 2012 | Volume: 2 | Issue: 11 | Pages: 1004-1023

10.1158/2159-8290.cd-12-0208 | PMID 23107779 Get It

Abstract Genetic lesions such as BCR–ABL1, E2A–PBX1, and MLL rearrangements (MLLr) are associated with unfavorable outcomes in adult B-cell precursor acute lymphoblastic leukemia (B-ALL). Leukemia oncoproteins may directly or indirectly disrupt cytosine methylation patterning to mediate the malignant phenotype. We postulated that DNA methylation signatures in these aggressive B-ALLs would point toward disease mechanisms and useful biomarkers and therapeutic targets. We therefore conducted DNA methylation and gene expression profiling on a cohort of 215 adult patients with B-ALL enrolled in a single phase III clinical trial (ECOG E2993) and normal control B cells. In BCR–ABL1-positive B-ALLs, aberrant cytosine methylation patterning centered around a cytokine network defined by hypomethylation and overexpression of IL2RA(CD25). The E2993 trial clinical data showed that CD25 expression was strongly associated with a poor outcome in patients with ALL regardless of BCR–ABL1 status, suggesting CD25 as a novel prognostic biomarker for risk stratification in B-ALLs. In E2A–PBX1-positive B-ALLs, aberrant DNA methylation patterning was strongly associated with direct fusion protein binding as shown by the E2A–PBX1 chromatin immunoprecipitation (ChIP) sequencing (ChIP-seq), suggesting that E2A–PBX1 fusion protein directly remodels the epigenome to impose an aggressive B-ALL phenotype. MLLr B-ALL featured prominent cytosine hypomethylation, which was linked with MLL fusion protein binding, H3K79 dimethylation, and transcriptional upregulation, affecting a set of known and newly identified MLL fusion direct targets with oncogenic activity such as FLT3 and BCL6. Notably, BCL6 blockade or loss of function suppressed proliferation and survival of MLLr leukemia cells, suggesting BCL6-targeted therapy as a new therapeutic strategy for MLLr B-ALLs. Significance: We conducted the first integrative epigenomic study in adult B-ALLs, as a correlative study to the ECOG E2993 phase III clinical trial. This study links for the first time the direct actions of oncogenic fusion proteins with disruption of epigenetic regulation mediated by cytosine methylation. We identify a novel clinically actionable biomarker in B-ALLs: IL2RA(CD25), which is linked with BCR–ABL1 and an inflammatory signaling network associated with chemotherapy resistance. We show that BCL6 is a novel MLL fusion protein target that is required to maintain the proliferation and survival of primary human adult MLLr cells and provide the basis for a clinical trial with BCL6 inhibitors for patients with MLLr. Cancer Discov; 2(11); 1004–23. ©2012 AACR. Read the Commentary on this article by Cimmino and Aifantis, p. 976. This article is highlighted in the In This Issue feature, p. 961
Proximal femoral density distribution and structure in relation to age and hip fracture risk in women
Carballido‐Gamio, Julio , Harnish, Roy, Saeed, Isra, Streeper, T., Sigurðsson, Sigurður , Amin, Shreyasee , Atkinson, Elizabeth J. , Therneau, Terry M. , Siggeirsdóttir, Kristín , Melton, L. Joseph , Keyak, Joyce H. , Guðnason, Vilmundur , Khosla, Sundeep , Harris, Tamara B. , Lang, Thomas , Cheng, Xiaoguang , Khosla, Sundeep

Mayo Clinic

Journal of Bone and Mineral Research | October 29, 2012 | Volume: 28 | Issue: 3 | Pages: 537-546

10.1002/jbmr.1802 | PMID 23109068 Get It

Abstract Hip fracture risk rises exponentially with age, but there is little knowledge about how fracture-related alterations in hip structure differ from those of aging. We employed computed tomography (CT) imaging to visualize the three-dimensional (3D) spatial distribution of bone mineral density (BMD) in the hip in relation to age and incident hip fracture. We used intersubject image registration to integrate 3D hip CT images into a statistical atlas comprising women aged 21 to 97 years (n = 349) and a group of women with (n = 74) and without (n = 148) incident hip fracture 4 to 7 years after their imaging session. Voxel-based morphometry was used to generate Student's t test statistical maps from the atlas, which indicated regions that were significantly associated with age or with incident hip fracture. Scaling factors derived from intersubject image registration were employed as measures of bone size. BMD comparisons of young, middle-aged, and older American women showed preservation of load-bearing cortical and trabecular structures with aging, whereas extensive bone loss was observed in other trabecular and cortical regions. In contrast, comparisons of older Icelandic fracture women with age-matched controls showed that hip fracture was associated with a global cortical bone deficit, including both the superior cortical margin and the load-bearing inferior cortex. Bone size comparisons showed larger dimensions in older compared to younger American women and in older Icelandic fracture women compared to controls. The results indicate that older Icelandic women who sustain incident hip fracture have a structural phenotype that cannot be described as an accelerated pattern of normal age-related loss. The fracture-related cortical deficit noted in this study may provide a biomarker of increased hip fracture risk that may be translatable to dual-energy X-ray absorptiometry (DXA) and other clinical images. © 2013 American Society for Bone and Mineral Research.
Lenalidomide-mediated enhanced translation of C/EBPα-p30 protein up-regulates expression of the antileukemic microRNA-181a in acute myeloid leukemia
Hickey, Christopher , Schwind, Sebastian , Radomska, Hanna S. , Dorrance, Adrienne M. , Santhanam, Ramasamy , Mishra, Anjali , Wu, Yue-Zhong, Alachkar, Houda , Maharry, Kati , Mrózek, Krzysztof , Eiring, Anna M. , Whitman, Susan P., Becker, Heiko , Perrotti, Danilo , Wu, Lai‐Chu , Zhao, Xi , Fehniger, Todd A. , Vij, Ravi , Byrd, John C. , Blum, William , Lee, L. James , Bloomfield, Clara D. , Garzon, Ramiro , Marcucci, Guido , Byrd, John C. , Nicolet, Deedra , Walker, Alison , Caligiuri, Michael A. , Fehniger, Todd A , Byrd, John C

Mayo Clinic

Blood | October 26, 2012 | Volume: 121 | Issue: 1 | Pages: 159-169

10.1182/blood-2012-05-428573 | PMID 23100311 Get It

AbstractRecently, we showed that increased miR-181a expression was associated with improved outcomes in cytogenetically normal acute myeloid leukemia (CN-AML). Interestingly, miR-181a expression was increased in CN-AML patients harboring CEBPA mutations, which are usually biallelic and associate with better prognosis. CEBPA encodes the C/EBPα transcription factor. We demonstrate here that the presence of N-terminal CEBPA mutations and miR-181a expression are linked. Indeed, the truncated C/EBPα-p30 isoform, which is produced from the N-terminal mutant CEBPA gene or from the differential translation of wild-type CEBPA mRNA and is commonly believed to have no transactivation activity, binds to the miR-181a-1 promoter and up-regulates the microRNA expression. Furthermore, we show that lenalidomide, a drug approved for myelodysplastic syndromes and multiple myeloma, enhances translation of the C/EBPα-p30 isoform, resulting in higher miR-181a levels. In xenograft mouse models, ectopic miR-181a expression inhibits tumor growth. Similarly, lenalidomide exhibits antitumorigenic activity paralleled by increased miR-181a expression. This regulatory pathway may explain an increased sensitivity to apoptosis-inducing chemotherapy in subsets of AML patients. Altogether, our data provide a potential explanation for the improved clinical outcomes observed in CEBPA-mutated CN-AML patients, and suggest that lenalidomide treatment enhancing the C/EBPα-p30 protein levels and in turn miR-181a may sensitize AML blasts to chemotherapy.